Furthermore, damage of liver function and severity of liver fibrosis were measured using AST/ALT biochemical analysis and immunohistochemistry (IHC) against α-SMA, a maker for HSCs’ activation33, respectively, confirmed the advancing hepatic fibrosis (Fig. 3d, e). This evidence concerns the gene ACTA1 and Hepatic fibrosis.